Diklofenaakis

Diklofenaakis is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve pain and inflammation. It is the Greek-language transliteration of diclofenac and is employed in several countries under various brand names. The medication is available in multiple formulations, including oral tablets, topical gels for localized pain, and parenteral preparations in some markets.

Common medical uses include osteoarthritis and rheumatoid arthritis, acute musculoskeletal injuries, postoperative pain, dental pain, and dysmenorrhea. Topical forms provide localized relief with reduced systemic exposure compared with oral forms.

Mechanism of action: Diklofenaakis inhibits cyclooxygenase enzymes COX‑1 and COX‑2, leading to decreased synthesis of prostaglandins that mediate inflammation and pain. As with other NSAIDs, its effects reflect diminished inflammation and fever reduction.

Pharmacokinetics: After oral administration, the drug is absorbed rapidly, with peak plasma concentrations reached within a couple of hours. It is extensively bound to plasma proteins and undergoes hepatic metabolism, with elimination primarily via the kidneys.

Safety and adverse effects: Common adverse events include gastrointestinal symptoms such as nausea, dyspepsia, and abdominal pain, as well as headaches and dizziness. More serious risks involve gastrointestinal ulcers or bleeding, cardiovascular events, and renal or hepatic impairment, particularly with long-term use or higher doses. Diklofenaakis is contraindicated in individuals with active GI ulcers or bleeding, severe hepatic or renal impairment, during the third trimester of pregnancy, or known hypersensitivity to NSAIDs. Caution is advised in patients taking anticoagulants or other NSAIDs, and drug interactions may alter renal function or blood pressure control.

History: The compound follows the broader diclofenac class, first marketed in the 1970s. See also Diclofenac.